RBC Capital reiterates Bausch & Lomb stock rating on DED momentum
RBC Capital reiterated an Outperform rating and $21.00 price target on Bausch & Lomb (NYSE:BLCO), projecting Q3 2026 revenue of $1,375M and adjusted EBITDA of $275M. The company reported Q2 2026 revenue of $1.394B, up 9.1% YoY, and raised full-year guidance. Analysts predict 2026 EPS of $0.82. Key focus areas include dry eye disease treatments and upcoming product launches.
How this was made
The 30-second read
Why it matters
The upgraded target and above‑consensus forecasts suggest investors may bid the stock higher, but execution risk remains.
Market read
Guidance lift ahead of earnings could drive short‑term buying interest, while trial setbacks and regulatory issues temper the upside.
What to watch
Potential regulatory risk from the FDA warning letter to the Tampa facility.
Background
RBC Capital's reiteration and updated guidance come amid mixed trial results for a dry‑eye treatment and an FDA warning letter, providing a nuanced view of the company's near‑term prospects.
Ticker impact
RBC Capital reiterated an Outperform rating and issued a $21 price target, providing fresh Q3 2026 revenue and EBITDA estimates that are above consensus.
likely upward pressure as investors price in higher revenue and EBITDA forecasts
The new estimates exceed consensus and are accompanied by a higher price target, which typically drives buying interest ahead of the earnings release.
Market effects
Positive outlook may lift other ophthalmic and eye‑care stocks as the dry‑eye franchise shows strength.
U.S. market focus; limited regional effect.
Modest, confined to healthcare sector investors.
Counterpoint
If the guidance fails to materialize, the stock could face a sharp correction.
Key entities
- analystRBC Capital
Equity research firm providing the rating and price target.
- companyBausch & Lomb Corp.
Eye‑care company receiving the new guidance.
